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Background
The HCV is considered the main etiological agent
involved in the hepatitis parenteral transmission. The
most frequent genotypes in Brazil are 1, 2 and 3, and gen-
otype 1b is the most frequent in blood donors. Data from
the serological screening of the Foundation of Hematology
and Hemotherapy of Amazonas (FHEMOAM) show that
0.32% of donors are seropositivity for anti-HCV. Some
studies showed that 15 to 25% has good prognostic but
80% develops chronic hepatitis. The purpose study was to
describe the clinical course and immunological profile of
chronic infection by HCV in patients treated with inter-
feron-alpha and ribavirin.
Methods
Clinical and laboratory evaluation, including viral geno-
type, viral load, and cellular and humoral immune
response, during the first 24 weeks of therapy.
Results
Partial results showed that genotype 1 (51.72%) is more
prevalent in the Amazon, followed by 3 (31.03%) and
2 (17.24%). Significant changes of AST and ALT concen-
trations showed an increase in the 4 weeks of treatment.
We observed a trend to increase cell populations in time
0 (pretreatment) to lymphocyte (63.3 ± 88.7), monocytes
(10.6 ± 21.5), neutrophils (86.7 ± 126, 1), had not statisti-
cally significant difference. The analysis by flow cytometry
showed an increase in total T cells and CD4 + in 4 weeks,
returning to baseline at 12 and 24 weeks after treatment.
Furthermore, there was a decrease of LTCD8 + in 12 and
24 weeks after treatment.
Discussion
Partial results showed that HCV infection changes the
profile of immune response in treated of patients with
Interferon-alpha and ribavirin.
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